RSV Vaccination for Older Adults in Care Homes

Respiratory syncytial virus, or RSV, is widely known as a childhood illness, but it is also a serious cause of hospitalisation and death in older adults, and care home residents are among those at greatest risk. A significant expansion of RSV vaccine eligibility in 2026 now means many more care home residents qualify for protection, making this a genuinely timely topic for care staff to understand.

Who Is Now Eligible

Following a recommendation from the Joint Committee on Vaccination and Immunisation, the UK government accepted an expansion of RSV vaccine eligibility in February 2026, formally announced in April 2026. The expansion extends eligibility to adults aged 80 and over and to residents of care homes for older adults, alongside the existing eligibility for people turning 75 and those aged 75 to 79. Pregnant women from 28 weeks are also eligible, as maternal vaccination protects newborns during their first, most vulnerable months. For care home residents specifically, this means many people who were previously outside the standard eligibility window by age now qualify directly through their care home residency.

Why RSV Is a Serious Risk for Older Adults

RSV causes an estimated 9,000 hospital admissions annually among people over 75 in the UK, and the illness can progress to bronchitis, pneumonia, and significant breathing difficulty, with potentially fatal complications in older or frailer adults. Because early RSV symptoms can resemble a common cold — a runny nose, mild cough, low-grade fever — it is easy for a resident's illness to be under-recognised in its early stages, only for it to escalate quickly, particularly in residents who already have underlying respiratory or cardiac conditions. The vaccine is estimated to reduce the risk of RSV-related hospitalisation by around 75%, which represents a substantial reduction in serious illness for a single vaccination.

What This Means for Care Homes

Care providers should treat RSV vaccination with the same seriousness and proactive approach already applied to seasonal flu vaccination, ensuring eligible residents — and their families or representatives, where a resident lacks capacity to consent themselves — are properly informed about the vaccine and supported to access it, typically through the resident's GP practice or a visiting vaccination service. Given that this is a relatively recent expansion, some families and even some residents' own GP records may not yet reflect their new eligibility, so care staff are often well placed to prompt the conversation rather than assuming it will happen automatically through routine channels.

As with any vaccination programme, keeping accurate, up-to-date records of which residents have received the RSV vaccine, and flagging new residents' eligibility as part of admission processes, ensures the home does not miss opportunities to protect newly admitted residents who may not have received the vaccine at their previous address or before moving into care.

RSV Alongside Other Winter Respiratory Risks

RSV sits alongside influenza and, more recently, Covid-19 as one of the seasonal respiratory illnesses that disproportionately affect care home residents, and the same infection prevention principles apply across all three: good hand hygiene, prompt isolation of symptomatic residents, and appropriate use of PPE during an outbreak. This connects to the wider stewardship principle covered in antimicrobial resistance and responsible antibiotic use, since preventing a viral respiratory infection through vaccination reduces the risk of a secondary bacterial infection that might otherwise require antibiotics. It also connects to the practical infection control measures covered in outbreak management, since a resident with RSV needs the same prompt recognition and isolation approach as any other infectious respiratory illness to prevent it spreading through the home.

Recognising RSV Symptoms Early

Because RSV often starts with symptoms indistinguishable from a common cold, staff familiarity with the pattern of deterioration matters as much as recognising the initial illness. Watch for a cold-like illness that does not improve after a few days, or that starts to worsen rather than settle — increasing breathlessness, a worsening cough, reduced oxygen saturation on a pulse oximeter where this is used, or a resident becoming increasingly fatigued or less responsive than usual. In residents with dementia, RSV can present atypically, sometimes with increased confusion or reduced alertness as the most obvious sign, rather than the respiratory symptoms being immediately prominent, which is part of why any unexplained deterioration in a resident during winter months should prompt consideration of a respiratory infection, not just be assumed to be "just a cold" or an unrelated change.

Where a resident's symptoms are escalating, the same structured escalation approach covered in recognising a deteriorating resident applies here as it would for any other acute illness — clear observation of vital signs, a low threshold for seeking a GP or 999 assessment where breathing difficulty is present, and accurate documentation of the pattern of deterioration to support whoever assesses the resident next.

Frequently Asked Questions

Who became newly eligible for the RSV vaccine in 2026?
Adults aged 80 and over and residents of care homes for older adults became newly eligible, alongside the existing eligibility for people aged 75 to 79 and pregnant women from 28 weeks.

How effective is the RSV vaccine at preventing serious illness?
The vaccine is estimated to reduce the risk of RSV-related hospitalisation by around 75%, a substantial reduction in serious illness from a single vaccination.

Why might care staff need to prompt the RSV vaccination conversation rather than wait for it to happen automatically?
Because this is a relatively recent eligibility expansion, some residents' GP records and families may not yet reflect their new eligibility, so care staff are often well placed to raise it proactively.